Glucos Fresenius Kabi

Glucos Fresenius Kabi is an intravenous solution for injection that contains glucose monohydrate as its sole active ingredient. Marketed in the European Union, the product is supplied as a sterile aqueous solution, though the exact concentration is not specified in the source data. It belongs to the carbohydrate class of parenteral nutrition products and is used to provide an immediate source of energy when administered intravenously.

Glucos Fresenius Kabi is indicated for several clinical situations where rapid glucose supplementation or fluid replacement is required.

- Parenteral nutrition to meet caloric needs when oral intake is insufficient. - Treatment of hypoglycemia in patients unable to receive oral glucose. - As a component of balanced electrolyte solutions for fluid resuscitation. - Support during peri‑operative fasting to maintain plasma glucose levels. - Adjunct in drug dilution for compatible intravenous medications.

When administered intravenously, Glucos Fresenius Kabi may be associated with a range of observed effects, most of which are related to the glucose load and the infusion process.

Common: - Transient hyperglycemia. - Local irritation or phlebitis at the infusion site. - Fluid overload in susceptible patients. - Mild electrolyte disturbances such as hyponatremia. - Nausea or mild headache. - Transient increase in serum osmolality.

Serious: - Severe hyperglycemia leading to ketoacidosis. - Anaphylactic or severe allergic reaction. - Hyperosmolar coma. - Severe fluid overload causing pulmonary edema. - Metabolic acidosis. - Life‑threatening electrolyte imbalance.

Clinicians should consider several precautionary measures before and during the use of Glucos Fresenius Kabi to minimize risks.

- Verify the patient’s baseline blood glucose and electrolyte levels prior to infusion. - Adjust infusion rate in individuals with renal or cardiac impairment. - Avoid rapid large‑volume administration in neonates and infants. - Monitor for signs of fluid overload, especially in patients with heart failure. - Use aseptic technique to prevent catheter‑related infections. - Assess compatibility with other IV drugs before mixing. - Consider the patient’s nutritional status and total caloric intake.

Glucose solutions can interact with other intravenous agents or patient conditions, influencing safety and efficacy.

Avoid: - Co‑administration with other hypertonic dextrose solutions that could precipitate severe hyperglycemia. - Mixing with calcium‑containing solutions that may cause precipitation. - Use with insulin infusions without appropriate glucose monitoring.

Use with caution: - Concurrent diuretics that may exacerbate electrolyte shifts. - Patients receiving beta‑blockers, as hypoglycemia symptoms may be masked. - Additional parenteral nutrition formulations to avoid excessive caloric load. - Vasopressors that may affect peripheral perfusion at the infusion site. - Medications that require strict glycemic control, such as certain chemotherapeutics.